Shanghai Allist Pharmaceuticals Co., Ltd.

Shanghai Allist Pharmaceuticals Co., Ltd. has experienced a recent evaluation adjustment, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company reported impressive financial metrics, including significant operating cash flow and net profit growth, highlighting its effective capital utilization and solid market position over the past ten quarters.

Shanghai Allist Pharmaceuticals Co., Ltd. faced a challenging trading session, with a notable stock decline. Over the past week and month, the stock has seen significant decreases, while year-to-date performance shows a marked drop. Despite this, the company reported strong financial metrics, including robust cash flow and net profit growth.

Shanghai Allist Pharmaceuticals Co., Ltd. has seen notable stock performance, gaining 5.71% on March 27, 2026, and reaching an intraday high of CNY 97.24. The company reported a net profit of CNY 1,187.76 million, with a growth rate of 59.72%, and maintains strong financial metrics.

Shanghai Allist Pharmaceuticals Co., Ltd. has shown strong performance, gaining 4.0% on March 24, 2026, and reaching an intraday high of CNY 91.83. Over the past year, the company has outperformed the China Shanghai Composite, with consistent positive results and robust financial metrics, including significant net profit growth.

Shanghai Allist Pharmaceuticals Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. Despite recent short-term setbacks, the company reported strong financial metrics, including substantial net profit growth and a high return on equity, maintaining its status in the pharmaceuticals sector.

Shanghai Allist Pharmaceuticals Co., Ltd. saw a decline in its stock today, contrasting with the broader market's performance. Despite recent short-term decreases, the company has shown resilience over the past year, achieving a notable return. It maintains a strong market position with impressive financial metrics and consistent positive results.

Shanghai Allist Pharmaceuticals Co., Ltd. has demonstrated notable stock performance, reaching an intraday high and outperforming the China Shanghai Composite over the past week. The company reported strong financials, including significant operating cash flow and net profit growth, while maintaining a solid market capitalization within the pharmaceuticals sector.

Shanghai Allist Pharmaceuticals Co., Ltd. faced a challenging trading session, with its stock declining significantly. However, the company has demonstrated resilience over the past week and maintains a strong market position in the pharmaceuticals sector, supported by solid financial metrics and recent growth in net profit and operating cash flow.

Shanghai Allist Pharmaceuticals Co., Ltd. saw a decline in its stock price today, reaching an intraday low. Despite this, the company reported strong financial health with a net profit increase of 59.72% and a robust return on equity of 29.94%, maintaining a significant market presence.

Shanghai Allist Pharmaceuticals Co., Ltd. has seen a notable rise in its stock performance, achieving an intraday high amid a declining market. The company has shown solid weekly gains and impressive one-year performance, supported by strong financial metrics, including significant operating cash flow and net profit growth.